Eli Lilly shares fall as sales of company’s weight-loss drug miss expectations
theglobeandmail.com/business/international-business/article-eli-lilly-shares-fall-as-sales-of-companys-weight-loss-drug-miss
Eli Lilly LLY-N on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound, came in slightly below Wall Street estimates, sending its shares down 4 per cent in premarket trading.
Separately, CVS Health CVS-N said that its pharmacy…
This story appeared on theglobeandmail.com, 2025-05-01 12:07:32.